Unlock the Future of Biologics & Protein Engineering
The event on May 8, 2025, at Foundry & Lux in South San Francisco offers biopharma professionals expert presentations on multispecific antibody workflows, computational developability assessments, and scaling biologics informatics, featuring BioGlyph's new solution BioGlyph Luma, followed by a live Q&A, panel discussion, and networking opportunities with industry leaders.
Join us for an exclusive evening of cutting-edge insights, expert discussions, and high-impact networking focused on the future of multispecific antibody and protein engineering. This event brings together leading minds in biopharma to explore next-generation biologics workflows and unveil BioGlyph Luma—a transformative solution designed to streamline antibody and protein engineering.
Event Details
- Date: Thursday, May 8, 2025
- Time: 5:00 PM – 7:30 PM
- Location: Foundry & Lux, 151 Oyster Point Blvd, South San Francisco, CA 94080
Agenda Highlights
Expert-Led Presentations: The Future of Biotherapeutics
"Building a Workflow for Multispecific Antibodies" – Daniel Keri, Head of Protein Engineering at BioGlyph
- Discover how multispecific antibodies enable novel therapeutic strategies.
- Learn the key challenges in designing and assembling complex antibody structures.
- Explore a next-generation workflow for predictable success in multispecific antibody engineering.
"In Silico Developability: Molecular Surface Descriptors & Conformational Sampling" – Eliot Park, Computational Scientist at BioGlyph
- Understand how computational tools can assess developability risks early.
- Learn how molecular surface descriptors impact biophysical property predictions.
- Discover six key in silico risk flags for identifying manufacturability challenges.
"Scaling Biological Informatics Ecosystems" – William Shirley, Executive Director, Research Informatics, Gilead Sciences
- Gain insights into integrating computational and experimental workflows at scale.
- Learn best practices for supporting large-scale biologics innovation.
Live Q&A and Industry Panel Discussion
- Engage with expert speakers in a moderated discussion led by BioGlyph founder, McClain Kressman.
- Explore the future of antibody and protein engineering with industry leaders.
Network with Industry Leaders
After the presentations, enjoy craft beer, wine, and appetizers while engaging in discussions with fellow scientists, researchers, and innovators. This is an opportunity to exchange ideas, build connections, and gain insider perspectives on the direction of the industry.
Why Attend?
- Be among the first to explore BioGlyph Luma, a revolutionary approach to antibody and protein engineering.
- Gain exclusive insights from top industry experts and researchers.
- Connect with leading scientists, computational biologists, and decision-makers in biopharma.
Space is limited—secure your place now and be part of this exciting launch event!
Related
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.
AE&T 2025: Full-Stack AI for Antibody Discovery
AE&T 2025 marked a pivotal shift in antibody R&D where AI-native, full-stack discovery systems seamlessly integrated in vitro, in vivo, and in silico workflows into a unified "lab-in-a-loop," emphasizing platform-level developability and overcoming fragmented data and workflows to transform complex protein designs into reliable therapeutics beyond oncology.
Multispecific Antibodies: Engineering the Non-natural
The article discusses the challenges and innovations in designing multispecific antibodies (MsAbs)—complex, non-natural biologics aimed at treating difficult diseases beyond the scope of traditional monoclonal antibodies—highlighting the need for advanced, flexible, AI-powered in silico design tools, such as those developed by Dotmatics and BioGlyph, that use building-block-based approaches to enable researchers to engineer novel biologic formats beyond rigid, predefined structures.
Dotmatics Announces Investment in BioGlyph for Visualizing, Illustrating, and Modeling Multispecific Antibodies
Dotmatics has made a significant minority investment in BioGlyph, a biotech software startup specializing in proprietary technology to visually illustrate, register, and model multispecific antibodies (MsAbs), aiming to accelerate protein therapeutic development by addressing the growing need for advanced software tools that support complex antibody formats beyond traditional monoclonal antibodies, complementing Dotmatics' new scientific intelligence platform, Luma.
BioGlyph Luma: Protein Design and Computational Modeling Platform
BioGlyph Luma is a next-generation protein design platform that integrates molecular modeling, production, and characterization into a seamless, traceable workflow, automates data management by converting LC-MS data into actionable insights, and connects with industry-standard tools to accelerate biologic discovery and optimize precision in protein and antibody engineering.
A Universal Language for Multispecific Antibodies
The article discusses the challenges of naming structurally diverse multispecific antibodies (MsAbs) and advocates for a building-block-based nomenclature system that captures both component parts and assembly logic, thereby enhancing collaborative research, enabling precise differentiation of complex biologics, and generating structured, AI-ready data to support current workflows and future protein engineering innovations.